Join
Live feed
·
PRReleasevia Quantisnow
Edgewise Therapeutics Inc. logo

Edgewise Therapeutics Announces Positive Topline Results from the EDG-5506 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HVs) and Doses First Becker Muscular Dystrophy (BMD) Patients

ByQuantisnow·Wall Street's wire, on your screen.
EWTX· Edgewise Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EWTX (Edgewise Therapeutics Inc.) and more on Quantisnow.